By targeting negative regulatory pathways such as programmed cell death protein 1 (PD-1), programmed death-ligand 1 (PD-L1), and cytotoxic T-lymphocyte–associated antigen 4 (CTLA-4), ICIs have demonstrated durable clinical benefits and survival advantages in a variety of tumor types (2). The gene discussed is PDCD1; the disease is neoplasm.